Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies

INTRODUCTION: Psoriasis affecting the head and neck can be difficult to treat, and the presence of extensive and highly visible lesions may result in substantial psychosocial burdens. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A, provides rapid and sustained clearance...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Dermatol Ther (Heidelb)
Hlavní autoři: Kircik, Leon, Fowler, Joseph, Weiss, Jonathan, Meng, Xiangyi, Guana, Adriana, Nyirady, Judit
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5120628/
https://ncbi.nlm.nih.gov/pubmed/27573260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-016-0139-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky